Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Fase III-studie i førstelinjebehandling av pasienter med metastatisk tykktarmskreft som ikke er kandidater for intensiv terapi. (SOLSTICE)

12. november 2026 oppdatert av: Institut de Recherches Internationales Servier

En åpen, randomisert, fase III-studie som sammenligner trifluridin/tipiracil (S 95005) i kombinasjon med bevacizumab med capecitabin i kombinasjon med bevacizumab i førstelinjebehandling av pasienter med metastatisk tykktarmskreft som ikke er kandidater for intensiv STUDIE (SOLICE)

The main purpose of this study is to demonstrate the superiority of S 95005 in combination with bevacizumab over capecitabine in combination with bevacizumab.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Faktiske)

856

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Berazategui, Argentina, B1884BBF
        • Centro de Oncología e Investigación de Buenos Aires COIBA
      • Buenos Aires, Argentina, C1426ANZ
        • Instituto Alexander Fleming
      • Buenos Aires, Argentina, C1093AAS
        • Fundación Favaloro Oncology Unit
      • Buenos Aires, Argentina, 1264
        • Hospital de Gastroenterología Dr. Carlos Borino Udaondo Oncology Unit
      • Buenos Aires, Argentina, C1431FWO
        • Hospital Universitario CEMIC Servicio de Oncología, Unidad de tumores gastrointestinales
      • La Rioja, Argentina, F5300COE
        • Centro Oncológico Riojano Integral CORI Fundación CORI para la Investigación y Prevención del Cáncer
      • Mendoza, Argentina, 5500
        • Fundación COIR Centro Oncológico de Interación Regional
      • San Miguel de Tucumán, Argentina, T4000IAK
        • Centro Médico San Roque
      • Santa Fe, Argentina, S3000FFU
        • ISIS Centro especializado
      • Santa Fe, Argentina, S2000KZE
        • Instituto de Oncología de Rosario
      • Blacktown, Australia, 2148
        • Blacktown Hospital Cancer and Haematology Centre
      • Frankston, Australia, 3199
        • Frankston Private Peninsula and Southeast Oncology Group
      • Gateshead, Australia, 2290
        • Lake Macquarie Private Hospital
      • Kogarah, Australia, 2217
        • St George Hospital St George Hospital Cancer Care Centre
      • Wahroonga, Australia, 2076
        • Adventist HealthCare Integrated Cancer Centre
      • Wollongong, Australia, 2500
        • Southern Medical Day Care Centre
      • Barretos, Brasil, 14784-400
        • Hospital do Câncer de Barretos - Fundação Pio XII Unidade de Pesquisa Clínica
      • Belo Horizonte, Brasil, 30150-320
        • Cenantron - Clinica
      • Brasília, Brasil, 70200-730
        • Sirio Libanes DF - Centro de Oncologia de Braslia do Sirio- Centro Intergrado de Pesquisa
      • Ijuí, Brasil, 98700-000
        • Centro de Pesquisa Hospital de Caridade de Ijuí Unidade de Pesquisa Clínica
      • Porto Alegre, Brasil, 90880-480
        • Hospital Mae de Deus Oncologia
      • Salvador, Brasil, 41253-191
        • Hospital São Rafael Centro Intergrado de Pesquisa
      • Santo André, Brasil, 09060-870
        • CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncol Centro Intergrado de Pesquisa
      • São José do Rio Preto, Brasil, 15090-000
        • Hospital de Base Centro Integrado de Pesquisa
      • São Paulo, Brasil, 01246-000
        • ICESP - Instituto do Câncer do Estado de São Paulo Centro Integrado de Pesquisa
      • São Paulo, Brasil, 01509-900
        • Hospital A C Camargo Unidade de Pesquisa Clinica
      • Burgas, Bulgaria, 8000
        • "Complex oncology center - Burgas" EOOD Department of medical oncology
      • Gabrovo, Bulgaria, 5300
        • "Multiprofile hosp. for active treatmen Dr. Tota Venkova" AD Department of medical oncology
      • Plovdiv, Bulgaria, 4004
        • "Complex oncology center - Plovdiv" EOOD, IInd base Dpt. of Med. oncology and onc. diseases in gastroenterology
      • Sofia, Bulgaria, 1330
        • "Medical Center Nadezhda Clinical" EOOD Medical Oncology Department
      • Sofia, Bulgaria, 1431
        • "UMHAT Sv. Ivan Rilski" EAD Clinic of clinical hematology, Dpt. of medical oncology
      • Sofia, Bulgaria, 1632
        • MHAT Serdika EOOD Department of Medical Oncology
      • Sofia, Bulgaria, 1756
        • Spec. hospital for active treatment of oncology dis. EOOD Department of medical oncology and palliative care
      • Varna, Bulgaria, 9003
        • SHAT of oncology diseases Dr. Marko Antonov Markov" EOOD Department of medical oncology and palliative therapy
      • Vratsa, Bulgaria, 3000
        • "Complex Ongology Center - Vratsa" EOOD Department of Medical oncology
      • Aalborg, Danmark, 9000
        • Aalborg Universitetshospital, Syd Onkologisk Afdelin
      • Copenhagen, Danmark, 2100
        • Rigshospitalet Onkologisk Klinik
      • Herning, Danmark, 7400
        • Regionshospitalet Herning, Hospitalsenheden Vest Onkologisk Afdeling
      • Odense, Danmark, 5000
        • Odense Universitetshospital Onkologisk Afdeling R
      • Tallinn, Estland, 11312
        • East Tallinn Central Hospital Center of Oncology
      • Tallinn, Estland, 13419
        • North Estonia Medical Centre Foundation Oncology and Haematology clinic
      • Tartu, Estland, 51014
        • Tartu University Hospital, Hematology - Oncology clinic, Radiotherapy and oncological therapy
      • Avignon, Frankrike, 84918
        • Institut Sainte Catherine
      • Besançon, Frankrike, 25030
        • CHU Jean Minjoz Service d'oncologie médicale
      • Brest, Frankrike, 29200
        • CHU Morvan Institut de Cancérologie et d'Hématologie
      • Lyon, Frankrike, 69008
        • Hopital Privé Jean Mermoz Service de Gastro entérologie et d'Oncologie médicale
      • Montbéliard, Frankrike, 25209
        • Hôpital Nord Franche-Comté - Site du Mittan Service d'oncologie médicale
      • Nice, Frankrike, 06189
        • Centre Antoine Lacassagne Dpt d'Oncologie Médicale
      • Paris, Frankrike, 75012
        • Hôpital Saint-Antoine Service d'Oncologie Médicale
      • Paris, Frankrike, 75015
        • Hôpital Européen Georges Pompidou Oncologie Hépatogastroenterologie-oncologie digestive
      • Pessac, Frankrike, 33604
        • Hopital Haut-Leveque Hepato-gastroenterologie et oncologie digestive
      • Toulouse, Frankrike, 31059
        • CHU Toulouse Rangueil Oncologie médicale digestive
      • Cork, Irland, 90
        • Bon Secours Hospital
      • Cork, Irland, T12 DC4A
        • Cork University Hospital Department of Medical Oncology
      • Dublin, Irland, D24 NROA
        • The Adelaide and Meath Hospital
      • Cagliari, Italia, 09100
        • Azienda Policlinico Universitaria - Presidio Monserrato Oncologia Medica
      • Cremona, Italia, 26100
        • Azienda Socio Sanitaria Territoriale di Cremona ONCOLOGIA
      • Naples, Italia, 80131
        • Istituto Nazionale Tumori I.R.C.C.S "Fondazione G. Pascale" Struttura Complessa di Oncologia Medica Addominale
      • Padova, Italia, 35128
        • Istituto Oncologico Veneto IOV - IRCCS Unità Operativa Complessa Oncologia Medica 1
      • Pisa, Italia, 56126
        • A.O.U. Pisana-Ospedale Santa Chiara U.O. di Oncologia Medica 2
      • Potenza, Italia, 85100
        • Ospedale San Carlo U.O. Oncologia Medica
      • Reggio Emilia, Italia, 42123
        • Arcispedale Santa Maria Nuova Unità di Oncologia
      • Roma, Italia, 00128
        • Policlinico Universitario Campus Biomedico UOC di Oncologia Medica
      • Rozzano (MI), Italia, 20089
        • Istituto Clinico Humanitas I.R.C.C.S Dipartimento di Oncologia Medica ed Ematologia
      • San Giovanni Rotondo, Italia, 71013
        • IRCSS Casa Sollievo della Sofferenza Dipartimento Onco-Ematologia
      • Vicenza, Italia, 36100
        • Ospedale S. Bortolo -ULSS8 Berica Distretto Est U.O. ONCOLOGIA
      • Riga, Latvia, 1079
        • Riga East Univerity Hospital Oncology Centre of Latvia
      • Riga, Latvia, 1002
        • P. Stradins Clinical University Hospital
      • Kaunas, Litauen, 45434
        • Oncology Hospital, Branch of Hospital of Lithuanian Uni. of Health Sciences Kauno klinikos
      • Kaunas, Litauen, LT-50161
        • Hospital of Lithuania Univ of Health Sciences Kauno klinikos Oncology Institute
      • Klaipėda, Litauen, 92288
        • Klaipeda University hospital
      • Vilnius, Litauen, LT-08660
        • National Cancer Institute
      • Arnhem, Nederland, 6815 AD
        • Rijnstate Oncologie
      • Dordrecht, Nederland, 3318 AT
        • Albert Schweitzer Ziekenhuis Interne Geneeskunde
      • Eindhoven, Nederland, 5623 EJ
        • Catharina Ziekenhuis Interne Gesneeskunde/Oncologie
      • Rotterdam, Nederland, 3083 AN
        • Ikazia Ziekenhuis Oncologie
      • Tilburg, Nederland, 5022 GC
        • ETZ Elisabeth Interne Geneeskunde
      • Uden, Nederland, 5406 PT
        • Bernhoven Interne Geneeskunde
      • Bialystok, Polen, 15-027
        • Bialostockie Centrum Onkologii im Marii Curie-Sklodowskiej Oddzial Onkologii Klinicznej im Dr Ewy Pileckiej z pododdzialem Chemioterapii Dziennej
      • Gdansk, Polen, 80-952
        • Uniwersyteckie Centrum Kliniczne Klinika Onkologii i Radioterapii
      • Konin, Polen, 62-500
        • Przychodnia Lekarska "KOMED"
      • Lodz, Polen, 93-513
        • M. Kopernika Provincial Hospital Oddzial Chemioterapii Nowotworow
      • Olsztyn, Polen, 10-228
        • SPZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii Oddzial Kliniczny Onkologii i Immunoonkologii
      • Opole, Polen, 45-061
        • Opolskie Centrum Onkologii im. Tadeusza Koszarowskiego Oddzial Onkologii Klinicznej
      • Poznan, Polen, 61-866
        • Wielkopolskie Centrum Onkologii im Marii Sklodowskiej-Curie Oddzial Chemioterapii
      • Tomaszów Mazowiecki, Polen, 97-200
        • NU-MED Centrum Diagnostyki i Terapii Onkologicznej Tomaszów Mazowiecki II Sp. z o.o., Pododdzial Chemioterapi
      • Almada, Portugal, 2805-267
        • Hospital Garcia de Orta Serviço de Oncologia Médica
      • Coimbra, Portugal, 3000-075
        • Centro Hospitalar e Universitário de Coimbra - CHUC Unidade de Inovação e Desenvolvimento (UID)
      • Lisbon, Portugal, 1649-035
        • Centro Hospitalar Lisboa Norte, Hospital de Santa Maria Serviço de Oncologia Médica
      • Loures, Portugal, 2674-514
        • Hospital Beatriz Ângelo Serviço de oncologia medic
      • Porto, Portugal, 4200-072
        • Instituto Português de Oncologia do Porto FG, EPE -IPO Porto Medical Oncology Dept.
      • Bucharest, Romania, 022328
        • Institutul Oncologic "Prof Alexandru Trestioreanu" Busuresti Sectia Oncologie Medicala I
      • Bucharest, Romania, 030171
        • Spitalul Clinic "Coltea" Sectia Oncologie Medicala
      • Cluj-Napoca, Romania, 400015
        • Institutul Oncologic "Prof. Dr. I. Chiricuta" Cluj Napoca Oncologie Medicala
      • Craiova, Romania, 200347
        • Centrul de Oncologie Sf Nectarie Oncology Department
      • Craiova, Romania, 200385
        • S.C Oncolab S.R.L Sectia Oncologie Medicala
      • Iași, Romania, 700483
        • Institutul Regional de Oncologie Iasi Clinica de Oncologie Medicala
      • Sibiu, Romania, 550245
        • Spitalul Clinic Judetean de Urgenta Sibiu Sectia Oncologie Medicala
      • Timișoara, Romania, 300239
        • S.C ONCOMED S.R.L Departament Oncologie Medicala
      • Arkhangelsk, Russland, 163045
        • Arkhangelsk Clinical Oncology Dispensary chemotherapy department
      • Krasnodar, Russland, 350040
        • Clinical Oncology Dispensary No.1 Chemotherapy Department
      • Kursk, Russland, 305524
        • Kursk Regional Clinical Oncology Dispensary Oncology Department
      • Moscow, Russland, 115478
        • Russian Cancer Research Center n.a. NN Blokhin Clinical Pharmacology and Chemotherapy
      • Moscow, Russland, 121467
        • University Headache Clinic Outpatient oncology clinic
      • Moscow, Russland, 143423
        • Moscow City Oncology Hospital # 62 chemotherapy department
      • Omsk, Russland, 644046
        • Omsk Clinical Oncologic Dispensary Chemotherapy
      • Pyatigorsk, Russland, 357502
        • Pyatigorsk Interdistrict Oncology Dispensary Chemotherapy department
      • Rostov-on-Don, Russland, 344037
        • Rostov Research Institute of Oncology Chemotherapy department
      • Ryazan, Russland, 390011
        • Regional Clinical Oncology Dispensary
      • Saint Petersburg, Russland, 115478
        • Scientific Centre for Specialized Medical Care (oncological) Chemotherapy
      • Saint Petersburg, Russland, 197758
        • National Medical Research Center of Oncology N.N. Petrova
      • Saint Petersburg, Russland, 198255
        • Saint Petersburg City Oncology Clilnic
      • Samara, Russland, 443011
        • Multidisciplinary clinic "Reaviz"
      • Sochi, Russland, 354057
        • Oncology Dispensary No.2
      • Tomsk, Russland, 634024
        • State Research Institution of Oncology of Tomsk Chemotherapy
      • Yaroslavl, Russland, 150054
        • SBIH of YR "Clinical oncology hospital" chemotherapy department
      • Bratislava, Slovakia, 833 10
        • Narodny onkologicky ustav Oddelenie klinickej onkologie
      • Košice, Slovakia, 04191
        • Vychodoslovensky onkologicky ustav Oddelenie klinickej onkologie
      • Alicante, Spania, 03010
        • Hospital General Universitario Alicante Servicio de Oncología
      • Badalona, Spania, 08916
        • Hospital Germans Trias i Pujol Unidad de Investigación clínica (UIC) ICO-Oncología medica
      • Barcelona, Spania, 08035
        • H. Valle de Hebrón Servicio de Oncología - (VHIR)
      • Barcelona, Spania, 08041
        • Hospital de la Santa Creu I Sant Pau Oncología Medica
      • Córdoba, Spania, 14004
        • Hospital Uni. Reina Sofía - Hospital Provincial Departamento de Oncología Médica
      • L'Hospitalet de Llobregat, Spania, 08908
        • INSTITUTO CATALAN DE ONCOLOGÍA - ICO Oncología Médica
      • Madrid, Spania, 28034
        • Hospital Universitario Ramón y Cajal, Servicio de Oncologia Médica
      • Madrid, Spania, 28007
        • Hospital Unviersitario Gregorio Marañon Servicio de Oncología Médica
      • Madrid, Spania, 28040
        • H. Clínico San Carlos Servicio de Oncología Médica
      • Madrid, Spania, 28041
        • HOSPITAL 12 DE OCTUBRE Servicio Oncología Médica
      • Madrid, Spania, 28046
        • H. Universitario La Paz Oncología Médica
      • Santander, Spania, 39008
        • Hospital Universitario Marqués de Valdecilla Oncología médica
      • Seville, Spania, 41013
        • H.Virgen Del Rocio
      • Valencia, Spania, 46010
        • Hospital Quirónsalud Valencia Servicio de Oncología Médica
      • Zaragoza, Spania, 50009
        • Hospital Universitario Miguel Servet Servicio de Oncología
      • Aberdeen, Storbritannia, AB25 2ZN
        • Aberdeen Royal Infirmary Oncology Department
      • Bristol, Storbritannia, BS2 8ED
        • University Hospitals Bristol Bristol Haematology & Oncology Centre
      • Leeds, Storbritannia, LS9 7TF
        • St James's University Hospital
      • Leicester, Storbritannia, LE1 5WW
        • Leicester Royal Infirmary The HOPE Clinical Trials Unit
      • London, Storbritannia, SW3 6JJ
        • Royal Marsden Hospital Department of Medicine
      • London, Storbritannia, W12 0HS
        • Hammersmith Hospital Gary Weston Centre
      • London, Storbritannia, W1G 6AD
        • Sarah Cannon Research Institute UK Clinical Trials
      • London, Storbritannia, W6 8RF
        • Imperial Healthcare NHS Trust Charing Cross Hospital
      • Manchester, Storbritannia, M20 4BX
        • Christie Hospital NHS Foundation Trust GI & Endocrine
      • Rhyl, Storbritannia, LL18 5UJ
        • Glan Clwyd Hospital North Wales Cancer Treatment Centre
      • Sutton, Storbritannia, SM2 5PT
        • Royal Marsden Hospital Department of Medicine
      • Falun, Sverige, 791 82
        • Falu Lasarett Onkologmottagningen
      • Jönköping, Sverige, 551 85
        • Lanssjukhuset Ryhov Onkologiska kliniken
      • Solna, Sverige, 171 64
        • Karolinska University Hospital, Solna Studiebehandlingsenheten, B8:09
      • Umeå, Sverige, 901 85
        • Norrlands Universitetssjukhus Cancercentrum Umea
      • Örebro, Sverige, 701 85
        • Universitetssjukhuset Orebro
      • Brno, Tsjekkia, 656 53
        • Masarykuv onkologicky ustav Klinika komplexni onkologicke pece
      • Ostrava, Tsjekkia
        • Fakultni nemocnice Ostrava Klinika onkologicka
      • Prague, Tsjekkia, 128 08
        • Vseobecna fakultni nemocnice Onkologicka klinika VFN a 1. LF UK
      • Prague, Tsjekkia, 140 59
        • Thomayerova nemocnice Onkologicka klinika 1. LF UK a TN
      • Prague, Tsjekkia, 77900
        • Fakultni nemocnice Olomouc Onkologicka klinika
      • Berlin, Tyskland, 10707
        • Onkologische Schwerpunktpraxis Kurfuerstendamm
      • Lübeck, Tyskland, 23562
        • Lübecker Onkologische Schwerpunktpraxis im Hochschulstadttei
      • München, Tyskland, 81377
        • Klinikum der Universität München Campus Großhadern, Medizinische Klinik und Poliklinik III
      • Cherkasy, Ukraina, 18009
        • Cherkasy Regional Oncological Dispensary Regional Clinical Oncological Centre
      • Dnipro, Ukraina, 49055
        • Dnipro Regional Oncology Dispensary
      • Dnipro, Ukraina, 49102
        • MI "Dnipropetrovsk City Multi-field Clinical Hospital #4" Department of Oncology
      • Kharkiv, Ukraina, 61024
        • Institute of Medical Radiology of S.P. Grygoryev of AMS UKR
      • Kyiv, Ukraina, 03022
        • National Institute of Cancer Abdominal Oncology Department
      • Kyiv, Ukraina, 03115
        • Kyiv City Clinical Oncology Centre Chemotherapy Department #2
      • Kyiv, Ukraina, 04107
        • Municipal Institution of Kyiv Regional Council "Kyiv Regional Clinical Hospital", proctology department
      • Lviv, Ukraina, 79031
        • Lviv Regional Oncology Center Chemotherapy department
      • Odesa, Ukraina, 65010
        • Odesa Regional Oncology Dispensary Day patient Department
      • Vinnytsia, Ukraina, 21029
        • Podillia Regional Oncology Centre Chemotherapy Department
      • Zaporizhzhya, Ukraina, 69000
        • Regional Clinical Oncological Dispensary Department of Oncology
      • Budapest, Ungarn, 1062
        • Magyar Honvedseg Egeszsegugyi Kozpont Onkologiai Osztaly
      • Budapest, Ungarn, 1083
        • Semmelweis University Radiology and Oncotherapy Clinic
      • Budapest, Ungarn, 1097
        • Del-Pesti Centrumkh-Orsz. Hematologiai es Infektologiai Int. Szent Laszlo Telephely
      • Budapest, Ungarn, 1115
        • Szent Imre Egyetem Oktatokorhaz Klinikai Onkologia
      • Budapest, Ungarn, 1122
        • Orszagos Onkologiai Intezet "B" Belgyogyaszati-Onkologiai O. Es Klin. Farmakologiai O.
      • Budapest, Ungarn, 1145
        • Uzsoki Utcai Korhaz Onkoradiologiai Osztaly
      • Debrecen, Ungarn, 4032
        • Debreceni Egyetem Orvos es Egeszsegtudomanyi Centrum Onkologiai Intezet
      • Gyula, Ungarn, 57000
        • Bekes Megyei Kozponti Korhaz
      • Győr, Ungarn, 9024
        • Petz Aladar Megyei Oktato Korhaz Onkoradiologiai Osztaly
      • Kecskemét, Ungarn, 6000
        • Bacs-Kiskun Megyei Korhaz Onkoradiologiai Kozpont
      • Nyíregyháza, Ungarn, 4400
        • Szabolcs-Szatmar-Bereg Megyei Korhazak Onkoradiologiai Osztaly
      • Pécs, Ungarn, 7624
        • Pecsi Tudomanyegyetem, Klinikai Kozpont Onkoterapias Intezet
      • Szeged, Ungarn, 6720
        • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kp. Onkoterápiás Klinika
      • Szolnok, Ungarn, 5004
        • JNSZ Megyei Hetenyi Geza Korhaz es Rendelointezet Megyei Onkologiai Centrum
      • Szombathely, Ungarn, 9700
        • Markusovsky Egyetemi Oktatokorhaz Onkoradiologiai Osztaly
      • Zalaegerszeg, Ungarn, 8900
        • Zala Megyei Korhaz Onkologiai osztaly
      • Graz, Østerrike, 8036
        • Med. Universität Graz Klinische Abteilung für Onkologie
      • Innsbruck, Østerrike, 6020
        • Medizinische Universität Innsbruck Univ.-Klinik für Innere Medizin V
      • Linz, Østerrike, 4010
        • Ordensklinikum Linz Barmherzige Schwestern Interne I
      • Salzburg, Østerrike, 5020
        • Landeskrankenhaus (SALK) Universitätsklinik für Innere Medizin III (SALK)
      • Sankt Pölten, Østerrike, 3100
        • Universitätsklinikum St. Pölten Klinische Abteilung für Innere Medizin I
      • Vienna, Østerrike, 1090
        • Allgemeines Krankenhaus - Universitätskliniken Klinische Abteilung für Onkologie

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Has definitive histologically confirmed adenocarcinoma of the colon or rectum (all other histological types are excluded). Primary tumour localisation must be known.

  2. RAS status based on local biological assessment of tumour biopsy must be available. If RAS status is not available at the time of randomisation, tumour biopsy must be available for RAS status determination (based on local biological assessment).

  3. Patient is not a candidate for standard full dose combination chemotherapy with irinotecan or oxaliplatin

  4. Patient is not a candidate for curative resection of metastatic lesions.

  5. No previous systemic anticancer therapy for unresectable metastatic colorectal cancer.

  6. ECOG (Eastern Cooperative Oncology Group) performance status ≤2.

  7. Adequate organ function (renal, haematological, hepatic, coagulation) as described in the study protocol'

    Exclusion Criteria:

  8. Pregnancy, breastfeeding or possibility of becoming pregnant during the study.

  9. Participation in another interventional study within 4 weeks prior to the randomisation .

  10. Patients who have not recovered from clinically relevant non-hematologic CTCAE grade ≥ 3 toxicity of previous anticancer therapy prior to the randomisation.

  11. Symptomatic central nervous system metastases.

  12. Major surgery within 4 weeks prior to the randomisation.

    Exclusion criteria related to S 95005 administration:

  13. History of allergic reactions attributed to compounds of similar composition to S 95005 or any of its excipients.

  14. Any contraindication present in the SmPC of trifluridine/tipiracil

    Exclusion criteria related to bevacizumab administration:

  15. Any contraindication present in the SmPC of bevacizumab

    Exclusion criteria related to capecitabine administration:

  16. Any contraindication present in the SmPC of capecitabine

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: S95005 + Bevacizumab

Film-coated tablets of S 95005 (35 mg/m²/dose) will be administered orally twice a day (BID), within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest; This treatment cycle will be repeated every 4 weeks.

Concentrate for solution for infusion, Bevacizumab (5 mg/kg, IV) administered every 2 weeks (Day 1 and Day 15). This treatment cycle will be repeated every 4 weeks.

Aktiv komparator: Capecitabin + Bevacizumab

Film-coated tablets, Capecitabine (1250 mg/m²/dose) will be administered orally BID on Days 1-14 of each cycle. This treatment cycle will be repeated every 3 weeks.

Concentrate for solution for infusion, Bevacizumab (7.5 mg/kg, IV) will be administered on Day 1 of each cycle.This treatment cycle will be repeated every 3 weeks.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Progression-free Survival (PFS)
Tidsramme: Up to 24 months

Time elapsed between the randomization and the date of radiological tumour progression (according to RECIST 1.1) or death from any cause.

Up to 24 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Forekomst av bivirkninger (AEs)
Tidsramme: Opptil 8 år
Opptil 8 år
Antall klinisk signifikante endringer i hematologi, biokjemi, koagulasjon og urinanalyse
Tidsramme: Opptil 8 år
Opptil 8 år
Endringer i ECOG ytelsesstatus
Tidsramme: Opptil 8 år
Opptil 8 år
Antall klinisk signifikante endringer i blodtrykk, hjertefrekvens, kroppstemperatur og kroppsvekt
Tidsramme: Opptil 8 år
Opptil 8 år
Antall klinisk signifikante endringer i 12-avlednings EKG-parametere
Tidsramme: Opptil 8 år
Opptil 8 år
Overall Survival (OS)
Tidsramme: Up to 8 years

Time elapsed between the date of randomization and the date of death due to any cause.

Up to 8 years
Overall response rate (ORR)
Tidsramme: Up to 8 years

The proportion of patients with objective evidence of complete response (CR) or partial response (PR) according to RECIST 1.1 criteria and using investigator's tumour assessment.

Up to 8 years
Disease control rate (DCR)
Tidsramme: Up to 8 years

The proportion of patients with objective evidence of CR or PR or stable disease (SD) according to RECIST 1.1 criteria and using investigator's tumour assessment.

Up to 8 years
Duration of response (DoR)
Tidsramme: Up to 8 years

The time from the first documentation of response (CR or PR) to the first documentation of objective tumour progression or death due to any cause, whichever occurs first.

Up to 8 years
Time to treatment failure (TTF)
Tidsramme: Up to 8 years

The time from randomization to treatment discontinuation for any reason, including disease progression, treatment toxicity, patient preference, or death.

Up to 8 years
Quality of life as assessed by EORTC QLQ-C30
Tidsramme: Up to 8 years

European organization for research and treatment of cancer (EORTC) Quality of Life Questionnaire - Core Questionnaire (QLQ-C30) scores range from 0-100 and assess functional and symptom scores. For functional scores, a higher score represents an increase in functioning. For symptom scores, a higher score represents an increase in symptoms.

Up to 8 years
Quality of life as assessed by EQ-5D-5L
Tidsramme: Up to 8 years

The 5-level EQ-5D version questionnaire scores range from 5 to 25 with a higher score representing a worse health status.

Up to 8 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Thierry ANDRE, PhD, Medical Oncology departement Saint-Antoine hospital (Paris France 75012)

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

21. mars 2019

Primær fullføring (Faktiske)

29. juni 2021

Studiet fullført (Antatt)

31. desember 2026

Datoer for studieregistrering

Først innsendt

23. februar 2018

Først innsendt som oppfylte QC-kriteriene

8. mars 2019

Først lagt ut (Faktiske)

11. mars 2019

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

13. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • CL3-95005-006
  • 2017 (U.S. NIH-stipend/kontrakt)
  • 2017-004059-22 (EudraCT-nummer)
  • U1111-1206-3198 (Annen identifikator: UTN)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.

Access can be requested for all interventional clinical studies:

  • used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
  • where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.

In addition, access can be requested for all interventional clinical studies in patients:

  • sponsored by Servier
  • with a first patient enrolled as of 1 January 2004 onwards
  • for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.

IPD-delingstidsramme

After Marketing Authorisation in EEA or US if the study is used for the approval.

Tilgangskriterier for IPD-deling

Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • ICF
  • CSR

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .